Skip to main content

Market Overview

AbbVie's Allergan Files US Application AGN-190584 For Presbyopia

  • Allergan, an AbbVie Inc (NYSE: ABBV), has submitted a marketing application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the application by the end of 2021.
  • Presbyopia is a common and progressive eye condition that reduces the eye's ability to focus on near objects and usually impacts people after age 40.
  • AGN-190584 is an investigational optimized formulation of pilocarpine, a cholinergic muscarinic receptor agonist, which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle.
  • Price Action: ABBV is down 0.95% at $107.66 in market trading hours on the last check Thursday.

Related Articles (ABBV)

View Comments and Join the Discussion!

Posted-In: presbyopiaBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at